CN1575173A - Macrolides containing pharmaceutical compositions - Google Patents

Macrolides containing pharmaceutical compositions Download PDF

Info

Publication number
CN1575173A
CN1575173A CNA028211588A CN02821158A CN1575173A CN 1575173 A CN1575173 A CN 1575173A CN A028211588 A CNA028211588 A CN A028211588A CN 02821158 A CN02821158 A CN 02821158A CN 1575173 A CN1575173 A CN 1575173A
Authority
CN
China
Prior art keywords
chemical compound
amino
ammediol
formula
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CNA028211588A
Other languages
Chinese (zh)
Other versions
CN1307993C (en
Inventor
J·G·迈因加斯内
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0127341A external-priority patent/GB0127341D0/en
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1575173A publication Critical patent/CN1575173A/en
Application granted granted Critical
Publication of CN1307993C publication Critical patent/CN1307993C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Disclosed is a pharmaceutical composition comprising a compound of formula (I) and a pharmaceutically acceptable 2-amino-1,3-propanediol beside one or more pharmaceutically acceptable excipient(s).

Description

The pharmaceutical composition that contains macrolide
The present invention relates to pharmaceutical composition, for example be used for the treatment of pathological condition, comprise co-administered activating agent with pharmaceutically active.Treatment comprises and preventing and/or treating.
On the one hand, the invention provides the pharmaceutical active compounds of formula I,
Figure A0282115800041
As the disclosed chemical compound of EP427680 (the 33-table-33-chloro-FR520 among the embodiment 66a) and 2-amino-1, ammediol and one or more pharmaceutically useful excipient.
One or more pharmaceutically useful excipient for example comprise one or more pharmaceutically useful auxiliary agents, carrier, diluent.2-amino-1, ammediol can comprise one or more 2-amino-1, ammediol.
Known formula I chemical compound has activity for the various condition/disease of treatment, as for example inflammatory situation, immune-mediated disease, or autoimmune disease, vasculitis for example, glomerulonephritis (glomerulonephritides), atopic dermatitis, irritated (atopy contact eczema for example, asthma), psoriasis, systemic lupus erythematosus (sle), rheumatoid arthritis, inflammatory bowel (segmental enteritis for example, ulcerative colitis), multiple sclerosis, insulin dependent diabetes mellitus (IDDM), sjogren syndrome, endogenous posterior uveitis (uveitide) (especially behcet disease), chronic lymphocytic thyroiditis, and prevention xenograft or allograft, for example comprise heart, kidney, the repulsion that liver or bone marrow graft cause; Grafting vessel disease or graft versus host disease.
The 2-amino of herein mentioning-1, ammediol comprise formula II chemical compound,
Wherein:
R 1Be the optional straight or branched (C that replaces 12-22) carbochain, alkyl chain for example, it is optional be substituted or unsubstituted phenylene at interval, and R 2, R 3, R 4And R 5Be H or low alkyl group independently of one another.Work as R 1When the carbochain of indication was substituted, it was preferably by halogen, nitro, amino, hydroxyl or carboxyl substituted.The phenyl that is optionally substituted when carbochain is at interval the time, and carbochain is preferably unsubstituted.When phenylen moiety was substituted, it was preferably by halogen, nitro, amino, methoxyl group, hydroxyl or carboxyl substituted." low alkyl group " comprises (C 1-4) alkyl.These chemical compounds for example are disclosed among EP627406, EP778263, EP1002792 or the WO02/06268, and the content of its related content, especially relevant described chemical compound is hereby incorporated by.
Preferred chemical compound comprises formula II chemical compound, wherein R 1(C for straight or branched, preferred straight chain 13-20) carbochain, optional by nitro, halogen, amino, hydroxyl or carboxyl substituted, and more preferably formula II chemical compound, wherein R 1Be the optional phenylalkyl that is replaced by halogen, for example wherein alkyl is the optional (C that is replaced by hydroxyl 1-6) alkyl, and wherein phenyl by straight or branched (C 6-14) alkyl replaces and optionally replaced by halogen.More preferably, R 1Be phenyl (C 1-6) alkyl, phenyl wherein is by straight or branched, preferred straight chain (C 6-14) the alkyl replacement, as (C 6-14) alkyl-phenyl-(C 1-6) alkyl.If R 1Be phenylalkyl, phenyl wherein is by straight or branched (C 6-14) alkyl replaces, then phenyl can by alkyl at the ortho position, a position or para-position, preferably at para-orientation.Preferred R 2To R 5Each be H.
Pharmaceutical composition can comprise formula I chemical compound and 2-amino-propanol, for example a kind of 2-amino-propanol described in the EP778263, and one or more pharmaceutically useful excipient.
In a further preferred embodiment, 2-amino-1, ammediol or 2-amino-propanol are the chemical compound with lymphocyte homing character.This character can according to as for example following test differentiate: with test compound or excipient by raising by oral administration to rat by force.Got tail blood in 2,6,24,48 and 72 hours and be used for hematology's monitoring using the back, got tail blood to provide the baseline individual value in the 11st day.The lymphocyte homing agent is a kind of like this chemical compound: for example using less than 5mg/kg, preferably behind the dosage less than 3mg/kg, peripheral blood lymphocytes was being reduced in its 6 hours and surpass 50%.
Still preferred formula II chemical compound is a formula IIa chemical compound,
2-amino-2[2-(4-octyl phenyl) ethyl for example] propane-1, the 3-diol hydrochloride.Based on observed activity, for example described in the EP627406,2-amino-1, ammediol for example formula II chemical compound can be used as immunomodulator, for example for example immunosuppressant in the treatment allograft rejection.For example as described in the WO98/22100, the 2-amino-1 of formula II for example, ammediol can suppress the grafting vessel disease and be specially adapted to prevent or treat the chronic rejection of transplant organ, can suppress xenograft in addition and repel.
According to the present invention, 2-amino-1, ammediol or 2-amino-propanol have pharmaceutically active and are that pharmacy is acceptable.
As long as there is described form, formula I chemical compound and 2-amino-1, ammediol comprises any type of chemical compound, for example free form, salt form, solvate forms and salt and solvate forms.The The compounds of this invention of free form can change into the chemical compound of corresponding salt form; The free form of solvate forms or the The compounds of this invention of salt form can be converted into the free form of corresponding non-solvent compound form or the chemical compound of salt form, and vice versa.
The activity of the pharmaceutically active of the chemical compound of free form and the chemical compound of salt/solvate forms is in similar scope.Solvate comprises hydrate.Salt comprises pharmaceutically useful salt.
For example the officinal salt of formula II chemical compound comprises the salt that formula II chemical compound and acid form, described acid for example comprises mineral acid, example hydrochloric acid, hydrobromic acid and sulphuric acid, and comprise organic acid, as acetic acid, fumaric acid, maleic acid, benzoic acid, citric acid, malic acid, methanesulfonic acid and benzenesulfonic acid, if and had carboxyl, would also comprise the salt that forms with following material:
-metal such as sodium, potassium, calcium and aluminum,
-amine such as triethylamine and
-dibasic aminoacid such as lysine.
In a preferred embodiment, formula II chemical compound or the described chemical compound of those EP1002792 comprise the phosphate of described chemical compound.
Formula I chemical compound and formula II chemical compound can exist with isomeric form, and the present invention includes formula I chemical compound of the present invention and 2-amino-1, ammediol and any heterogeneous mixture of any isomeric form.If formula I chemical compound for example of the present invention and 2-amino-1, ammediol has one or more asymmetric centers in molecule, then the present invention includes the chemical compound of various optical isomer forms, and racemic modification, diastereomer and its mixture.
We now surprisingly find: formula I chemical compound or 2-amino-1 therein, ammediol can show in the animal model of experimental autoimmune uveitis (EVU) of pharmaceutically active, when with co-administered formula I chemical compound of for example suboptimum dosage and 2-amino-1, ammediol for example during formula II chemical compound, has obtained enhanced activity.The enhanced activity of co-administered chemical compound is significantly higher than the activity of every kind of unification compound being tested under suboptimum dosage level for example.It is believed that identical rule also is applicable to its Chinese style I chemical compound or 2-amino-1, ammediol shows all diseases of pharmaceutically active, for example comprise the inflammatory situation, immune-mediated disease, or autoimmune disease, vasculitis for example, glomerulonephritis, atopic dermatitis, irritated (atopy contact eczema for example, asthma), psoriasis, systemic lupus erythematosus (sle), rheumatoid arthritis, inflammatory bowel (segmental enteritis for example, ulcerative colitis), multiple sclerosis, insulin dependent diabetes mellitus (IDDM), sjogren syndrome, endogenous posterior uveitis (especially behcet disease), chronic lymphocytic thyroiditis, and prevent xenograft or allograft for example to comprise heart, kidney, the repulsion that liver or bone marrow graft cause; Grafting vessel disease or graft versus host disease.
On the other hand, the invention provides a kind of packing, it comprises the pharmaceutical composition of formula I chemical compound and one or more pharmaceutically acceptable excipient, and comprises and be used for simultaneously or use 2-amino-1, the description of ammediol successively.
On the other hand, the invention provides a kind of packing, it comprises 2-amino-1, the pharmaceutical composition of ammediol and one or more pharmaceutically acceptable excipient, and comprise the description that is used for simultaneously or uses formula I chemical compound successively.
On the other hand, the invention provides pharmaceutical pack, for example a kind of packing, it comprises the pharmaceutical composition of formula I chemical compound and one or more pharmaceutically acceptable excipient in same packing, and 2-amino-1, the pharmaceutical composition of ammediol and one or more pharmaceutically acceptable excipient.
On the other hand, the invention provides the method for the pharmaceutically active that improves foregoing formula I chemical compound, this method comprises to needs formula I chemical compound and/or 2-amino-1, the co-administered formula I chemical compound of object and the 2-amino-1 of ammediol treatment, ammediol.
Formula I chemical compound and 2-amino-1, ammediol can be co-administered in a different manner:
A), comprise the formula I chemical compound and the 2-amino-1 with pharmaceutically active, ammediol that are in the same pharmaceutical composition with the form of fixed combination;
B) with the form of (medicine) bag, its Chinese style I chemical compound and 2-amino-1, ammediol exists with the separated drug composition forms, for example be used for co-administered description and sell in same packing.
C) with the form of independent assortment, its Chinese style I chemical compound and 2-amino-1, ammediol is for example packed respectively with the form of pharmaceutical composition, and wherein each packing includes and is used for simultaneously or the description of using successively.
Formula I chemical compound and 2-amino-1, the most effective ratio of ammediol can be depending on indication for example to be treated.Appropriate dosage and dosage range will change according to for example employed reactive compound of the present invention, host, method of application and the sanatory character of institute and seriousness certainly.But, generally speaking, in order for example to realize satisfactory results in the human body bigger mammal, the daily dose that is suitable for is the formula I chemical compound of macrolide such as pharmaceutically active and the 2-amino-1 of pharmaceutically active, the known dose of ammediol, for example be lower than these optimal doses, for example use to be no more than divided dose, for example every day 4 times.Usually, obtain the satisfied needed daily dose of result at whole body and be the formula I chemical compound of about 0.5mg/kg to about 15mg/kg, preferred 1mg/kg to about 15mg/kg animal/body weight for humans and the formula II chemical compound of about 0.005mg/kg to 0.1mg/kg, preferred 0.01mg/kg to 0.1mg/kg.The ratio of preferred Compound I and II is about 3000 to 10, preferred 500 to 10.
Reactive compound of the present invention can be used by the approach of any routine, and is for example by whole body, for example oral, for example uses with tablet or capsular form; Or, for example use with the form of injection solution or suspension by parenteral; And use in local application such as epidermis, intranasal, the trachea.
On the other hand, the invention provides treatment its Chinese style I chemical compound and/or 2-amino-1, ammediol has the method for the disease of pharmaceutically active, described disease for example comprises the inflammatory situation, immune-mediated disease or autoimmune disease, vasculitis for example, glomerulonephritis, atopic dermatitis, irritated (atopy contact eczema for example, asthma), psoriasis, systemic lupus erythematosus (sle), rheumatoid arthritis, inflammatory bowel (segmental enteritis for example, ulcerative colitis), multiple sclerosis, insulin dependent diabetes mellitus (IDDM), sjogren syndrome, endogenous posterior uveitis (especially behcet disease) or chronic lymphocytic thyroiditis, and prevent xenograft or allograft for example to comprise heart, kidney, the repulsion that liver or bone marrow graft cause; Grafting vessel disease or graft versus host disease, described method comprise formula I chemical compound from effective dose to the object of this treatment of needs and the 2-amino-1 of using, and ammediol is for example used with following form:
-fixed combination, for example form of pharmaceutical composition;
-(medicine) wraps, and for example is in the pharmaceutical composition and the 2-amino-1 of the formula I chemical compound in the same packing, the form of the pharmaceutical composition of ammediol;
-a kind of packing comprises for example the formula I chemical compound or the 2-amino-1 of pharmaceutical compositions, ammediol, and comprise and be used for simultaneously or co-administered successively description.
In a preferred embodiment of the invention, formula I chemical compound and formula IIa chemical compound are co-administered.
Formula I chemical compound and 2-amino-1, ammediol can be used as unique composition or the other medicines in the immunomodulating scheme or other antiinflammatory and use.For example described chemical compound can use with following drug regimen: cyclosporin, rapamycin or other ascosin, or their immunosuppressant analog, for example cyclosporin A, cyclosporin G, FK-506, rapamycin, 40-O-(2-hydroxyl) ethyl-rapamycin etc.; Corticosteroid; Cyclophosphamide; Azathioprine; Methotrexate; Bai Ruikuaer; Take fluorine Lip river rice; Mizoribine; Mycophenolic acid; Mycophenolate; 15-deoxidation Antibiotic BMG-162aF2; The immunosuppressant monoclonal antibody is for example at leukocyte receptors for example MHC, CD2, CD3, CD4, CD7, CD25, CD28, B7, CD40, CD45 or CD58 or at their monoclonal antibody of part; Or other immunomodulatory compounds CTLA4-1g for example.
Be used to measure formula I chemical compound and 2-amino-1, the active test method(s) of ammediol is known.Can use for example Clin.Immunol.Immunopathol.1986,39:329-336, the described experimental autoimmune uveitis of people such as McAllister (EAU) model.
On the other hand, for example the invention provides simultaneously or formula I chemical compound and the 2-amino-1 used successively, ammediol is as the purposes of medicine; And formula I chemical compound and 2-amino-1, the preparation that is combined in of ammediol is used for the treatment of purposes in the medicine of disease, described disease Chinese style I chemical compound or 2-amino-1, and ammediol has pharmaceutically active.Treatment comprises and preventing and/or treating.
Brief description
Fig. 1 is presented at the result of experimental autoimmune uveitis (EAU) test of carrying out in the rat.
With following material oral medication rat once a day, 14 days by a definite date,
-◆-: contrast (placebo, i.e. drug excipient/water),
-■-: formula IIa chemical compound (0.1mg),
-▲-: formula I chemical compound (15mg), or
Formula IIa chemical compound (0.1mg)+formula I chemical compound (15mg).
Weight in mg is expressed as the mg/kg body weight/day.The scoring average of eyes infringements is measured as described in embodiment in back 20 days in immunity.
Fig. 2 is presented at the result of experimental autoimmune uveitis (EAU) test of carrying out in the rat.
With following material oral medication rat once a day, 14 days by a definite date,
-◆-: contrast (placebo, i.e. drug excipient/water),
-■-: formula IIa chemical compound (0.1mg),
-▲-: formula I chemical compound (15mg),
Formula I chemical compound (15mg)+formula IIa chemical compound (0.1mg), 14 days, or
-*-: formula I chemical compound (15mg)+formula IIa chemical compound (0.1mg), 28 days.
Other parameter as described in Figure 1.
Embodiment
Embodiment 1:EAU pilot system
Experimental autoimmune uveitis (EAU)
Employed EAU model class is similar to the previous described model of people such as McAllister (1986) (McAllister CG, Vistica BP, Sekura R, Kuwabara T, Gery l. " pertussis toxin, PT is to the uveitic effect of inducing and shifting of experimental autoimmune " Clin ImmunolImmunopathol 1986; 39:329-336).Under etherization, injected the bovine retina S-antigen of 50 μ g purification and through peritoneal injection 1 μ g pertussis toxin, PT (Difco) at first day to the right crus of diaphragm pad of animal (every group of 5 rats).Antigen mixes with Freund's complete adjuvant and Bacto M pulmonary tuberculosis H37 RA (Difco) with the saline dilution of phosphate-buffered and with 1: 1 ratio.Volume injected is 0.1ml, contains 50 μ l Freund's complete adjuvants and 1.14mg Mycobacterium tuberculosis.This operates in and all brings out burst (fulimant) disease in all animals, and it can be after immunity observes in initial 9 to 10 days.The eyes infringement of not treating animal all is developed to fractionated the 4th grade of seriousness (seeing " EAU evaluation " part) in nearly all animal.
Treatment, dosage
With gavage animal is treated, using daily dose is independent 15mg/kg formula I chemical compound or the formula IIa chemical compound of 0.1mg/kg, or uses two kinds of combination of compounds of same dose level.Treatment began in immunity in preceding 2 hours, and carried out once continuous 14 day every day.Control animal is with independent placebo/water (placebo: independent drug excipient) treat similarly.
EAU estimates
Beginning in the 7th day after immunity is with the inflammatory activity of ophthalmoscope (Heine, Beta 200) daily check animal, until the 20th day.The degree of eye inflammation is carried out semi-quantitative assessment with 0 to 4 classification (for eyes):
0: normal;
1: iris hyperemia;
2: iris hyperemia, comes expansion;
3: have early stage fibrin exudate and moderate iris cells to soak into the anterior chamber; With
4: have large-area fibre albumen grumeleuse or fibrin to stop up pupil and serious iris cells infiltration the anterior chamber.
The result
There are not significantly different (referring to for example table 1 and Fig. 1) aspect the process of disease and the intensity with the placebo group with the animal (LEWIS rat) of the formula I chemical compound oral administration treatment of the formula IIa chemical compound of 0.1mg/kg or 15mg/kg/ days.
In contrast, use two kinds of chemical compounds and make intensity that the outbreak of disease significantly postpones (than 6 days matched group evenings) and inflammation significantly with the same dose level a little less than.At the 19th day, the highest average score of treatment animal was 4.4, and the 11st day scoring of matched group is 8.0 by contrast.
Table 1
Test group Dosage ??EAU ??POS ????EAU10 ??EAU1 st ??????SCORE?MAX
Scoring My god
Contrast ??0.0 ??5/5 ????5/5 ??10.0(0.0) ??8.0(0.0) ??11
????Cpd?IIa ??0.1 ??4/4 *) ????2/5 ??10.5(0.6) ??8.0(0.0) ??13
????Cpd?I ??15 ??5/5 ????1/5 ??11.8(1.3) ??6.8(1.3) ??14
????Cpd?IIa+Cpd?I ??1.5+15 ??4/5 ????0/5 ??16(1.4) ??4.4(3.3) ??19
*)Experimental animal at the 11st day owing to wound due to raising by force comes off.
Under " the EAU POS " and " EAU10 " of table 1 item, shown every group of infected animal number/number of animals when research finishes (EAU POS) and the 10th day (EAU10) respectively.Used following abbreviation:
Cpd I: formula I chemical compound
Cpd IIa: formula IIa chemical compound
Contrast: placebo (drug excipient/water)
Dosage: oral, in mg/kg/ days
The positive number of rats of EAU POS:EAU
EAU10: the sickness rate of the 10th day EAU
EAU1 St: the date (mean value SD) of first EAU symptom
SCORE MAX: the highest scoring (the mean value SD of eyes infringement)
The result of EAU-test (as EXPERIMENTAL EXAMPLE) shows: the formula I chemical compound of suboptimum dosage and the formula IIa combination of compounds of suboptimum dosage significantly are being better than using separately respectively the formula I chemical compound of suboptimum dosage or the formula IIa chemical compound (table 1 and Fig. 1) of suboptimum dosage aspect the anti-EAU activity.This effect has approved that the formula I chemical compound of suboptimum dosage adds the use of the formula IIa chemical compound of suboptimum dosage.
Embodiment 2:
As the dosage treatment animal (every group of 6 rats) that provides as described in the embodiment 1, with table 2.As table 2 and shown in Figure 2, therapeutic alliance demonstrates the result who is better than with single compounds for treating.In the 14th day animal, in an animal, observed first clinical symptoms at the 16th day with two kinds of compounds for treating.Also observing symptom during the treatment in 4 weeks is suppressed fully.Symptom is early than the 34th day, and promptly last is treated and come across in the animal in back 6 days.
Table 2
Test group Dosage ??EAU?POS ???EAU ???10 ????EAU1 st ?????????SCORE?MAX
Scoring My god
Matched group ????- ??6/6 ???6/6 ????9.3(0.5) ??8.0(0.0) ??12
???Cpd?IIa ????0.1 ??6/6 ???0/6 ????11.2(1.0) ??8.0(0.0) ??14
???Cpd?I ????15 ??6/6 ???2/6 ????11.5(0.8) ??6.0(2.5) ??14
???Cpd?I+Cpd?IIa ????15+0.1(14x) ??6/6 ???0/6 ????18.0(1.1) ??8.0(0.0) ??21
???Cpd?I+Cpd?IIa ????15+0.1(28x) ??6/6 ???0/6 ????34.8(0.4) ??7.2(1.3) ??37
Implication is with the explanation of table 1.
The result of EAU test (as EXPERIMENTAL EXAMPLE) shows: when when immunity begins, carrying out 4 weeks treatments with the combination of Compound I and IIa, and the generation that can ward off disease.

Claims (10)

1. pharmaceutical composition, it comprises formula I chemical compound,
With 2-amino-1, ammediol, and one or more pharmaceutically useful excipient.
2. packing, it comprises the pharmaceutical composition of the defined formula I chemical compound of claim 1 and one or more pharmaceutically acceptable excipient, and comprises and be used for simultaneously or use 2-amino-1, the description of ammediol successively.
3. packing, it comprises 2-amino-1, the pharmaceutical composition of ammediol and one or more pharmaceutically acceptable excipient, and comprise the description that is used for simultaneously or uses the defined formula I chemical compound of claim 1 successively.
4. pharmaceutical pack, it comprises the pharmaceutical composition and the 2-amino-1 of the defined formula I chemical compound of the claim 1 that is in the same packing and one or more pharmaceutically acceptable excipient, the pharmaceutical composition of ammediol and one or more pharmaceutically acceptable excipient.
The defined formula I chemical compound of claim 1 with have the 2-amino-1 of pharmaceutically active, the combination of ammediol is as the purposes of medicine.
6. defined formula I chemical compound of claim 1 and 2-amino-1, the preparation that is combined in of ammediol is used for the treatment of purposes in the medicine of disease, described disease Chinese style I chemical compound and 2-amino-1, ammediol has pharmaceutically active.
7. improve formula I chemical compound and pharmaceutically useful 2-amino-1, the method for the pharmaceutically active of ammediol, this method comprise to needs formula I chemical compound and/or 2-amino-1, the co-administered formula I chemical compound of object and the 2-amino-1 of ammediol treatment, ammediol.
8. treat wherein defined formula I chemical compound of claim 1 and 2-amino-1, the method of the disease of ammediol tool pharmaceutically active, it comprises defined formula I chemical compound of claim 1 from effective dose to the object of this treatment of needs and the 2-amino-1 of using, ammediol.
9. each described method of aforementioned claim, pharmaceutical composition, pharmaceutical pack, packing or purposes, 2-amino-1 wherein, ammediol are formula II chemical compound,
Figure A028211580003C1
R wherein 1Be the optional straight or branched (C that replaces 12-22) carbochain, and R 2, R 3, R 4And R 5Be H or low alkyl group independently of one another.
10. the described method of claim 9, pharmaceutical composition, pharmaceutical pack, packing or purposes, its Chinese style II chemical compound has following general formula:
CNB028211588A 2001-10-23 2002-10-22 Macrolides containing pharmaceutical compositions Expired - Fee Related CN1307993C (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0125443.2 2001-10-23
GBGB0125443.2A GB0125443D0 (en) 2001-10-23 2001-10-23 Organic Compounds
GB0127341A GB0127341D0 (en) 2001-11-14 2001-11-14 Organic compounds
GB0127341.6 2001-11-14

Publications (2)

Publication Number Publication Date
CN1575173A true CN1575173A (en) 2005-02-02
CN1307993C CN1307993C (en) 2007-04-04

Family

ID=26246689

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028211588A Expired - Fee Related CN1307993C (en) 2001-10-23 2002-10-22 Macrolides containing pharmaceutical compositions

Country Status (19)

Country Link
US (1) US7259170B2 (en)
EP (1) EP1439838A1 (en)
JP (1) JP2005509634A (en)
KR (2) KR20090114483A (en)
CN (1) CN1307993C (en)
AU (1) AU2002346859C1 (en)
BR (1) BR0213463A (en)
CA (1) CA2458690C (en)
EC (1) ECSP045086A (en)
GB (1) GB0125443D0 (en)
HU (1) HUP0402108A3 (en)
IL (1) IL160973A0 (en)
MX (1) MXPA04003738A (en)
NO (1) NO20042074L (en)
NZ (1) NZ532412A (en)
PL (1) PL368533A1 (en)
RU (1) RU2321402C2 (en)
WO (1) WO2003035068A1 (en)
ZA (1) ZA200401711B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002089796A2 (en) * 2001-05-09 2002-11-14 Novartis Ag Methods for selective immunomodulation using pimecrolimus
KR100836547B1 (en) 2002-01-11 2008-06-10 상꾜 가부시키가이샤 Amino alcohol derivative or phosphonic acid derivative and medicinal composition containing these
GB0307867D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
BRPI0507944A (en) 2004-02-24 2007-07-24 Sankyo Co pharmaceutical composition

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68921934T2 (en) 1988-06-29 1995-10-19 Merck & Co Inc Immunosuppressive agent.
US5352671A (en) * 1989-11-09 1994-10-04 Sandoz Ltd. Heteroatoms-containing tricyclic compounds
ATE126803T1 (en) * 1989-11-09 1995-09-15 Sandoz Ag TRICYCLIC COMPOUNDS CONTAINING HETEROATOMS.
GB2252041A (en) * 1991-01-23 1992-07-29 Fujisawa Pharmaceutical Co Use of macrolide compounds in treatment of autoimmune myocarditis
JPH06509559A (en) * 1991-03-19 1994-10-27 セラピューティック　パッチ　リサーチ　エヌ．ブイ． Amino alcohol derivative compositions and methods as membrane permeation enhancers
GB9203636D0 (en) * 1992-02-19 1992-04-08 Lucas Ind Plc Fuel pumping apparatus
KR0155015B1 (en) 1992-10-21 1998-12-01 고우야 마사시 2-amino-1,3-propanediol compound and immunosuppressant
EP0689545A4 (en) 1993-03-17 1996-04-24 Abbott Lab Macrocyclic amide and urea immunomodulators
US5590460A (en) * 1994-07-19 1997-01-07 Tessera, Inc. Method of making multilayer circuit
ES2171191T3 (en) * 1994-08-22 2002-09-01 Mitsubishi Pharma Corp COMPOSITE OF BENZENE AND MEDICINAL USE OF THE SAME.
GB9521322D0 (en) 1995-10-17 1995-12-20 Sandoz Ltd Organic compounds
JPH11209277A (en) 1998-01-19 1999-08-03 Yoshitomi Pharmaceut Ind Ltd Pharmaceutical composition
GB9624038D0 (en) 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
DE69825056T2 (en) * 1997-04-04 2005-08-25 Mitsubishi Pharma Corp. 2-AMINOPROPAN-1,3-DIOL COMPOUNDS, THEIR MEDICAL APPLICATION AND INTERMEDIATES TO THEIR SYNTHESIS
GB9713730D0 (en) * 1997-06-30 1997-09-03 Ciba Geigy Ag Organic compounds
JP4627356B2 (en) * 1999-06-30 2011-02-09 松森　　昭 Drugs for preventing or treating viral myocarditis
GB0003932D0 (en) 2000-02-18 2000-04-12 Novartis Ag Pharmaceutical compositions
AU2002249826A1 (en) 2000-12-22 2002-07-30 Avantec Vascular Corporation Delivery of therapeutic capable agents

Also Published As

Publication number Publication date
KR100978971B1 (en) 2010-08-30
NZ532412A (en) 2006-01-27
AU2002346859B2 (en) 2006-03-02
ECSP045086A (en) 2004-06-28
GB0125443D0 (en) 2001-12-12
US20040192716A1 (en) 2004-09-30
HUP0402108A2 (en) 2005-02-28
KR20040052250A (en) 2004-06-22
NO20042074L (en) 2004-05-19
RU2321402C2 (en) 2008-04-10
CN1307993C (en) 2007-04-04
IL160973A0 (en) 2004-08-31
US7259170B2 (en) 2007-08-21
MXPA04003738A (en) 2004-07-23
RU2004116067A (en) 2005-04-20
HUP0402108A3 (en) 2008-02-28
AU2002346859C1 (en) 2008-07-10
CA2458690C (en) 2011-01-25
JP2005509634A (en) 2005-04-14
BR0213463A (en) 2004-11-09
WO2003035068A1 (en) 2003-05-01
ZA200401711B (en) 2004-10-21
PL368533A1 (en) 2005-04-04
CA2458690A1 (en) 2003-05-01
KR20090114483A (en) 2009-11-03
EP1439838A1 (en) 2004-07-28

Similar Documents

Publication Publication Date Title
CN1084618C (en) Use of serotonin antagonists (5HT3) for treating fibromyalgia
CN1145619C (en) 1-4-benzothiazepine-1,1-dioxide derivatives substituted by sugar radicals, methods for the production thereof, medicaments containing these compounds and the use thereof
RU2396982C2 (en) Effective method of using drugs and method for prevention of by-effects intensity
CN1213965A (en) Use of antiarrhythmic compounds for reducing post-infarction morality
CN1043610C (en) Novel treatment
KR101476591B1 (en) Treatment of autoimmune diseases
CN1152304A (en) Substituted benzamidines, their production and their use as medicaments
CN1522147A (en) Composition for treating drug-induced constipation with 15-keto-prostaglandins
CN1292694A (en) New use
CN1307993C (en) Macrolides containing pharmaceutical compositions
CN1170536C (en) Method for preventing vomit and sexual disorder using tetrahydrobenzo [cd] indole-6-formylamine compound
CN1340044A (en) Nervinolin derivatives
CN1684681A (en) Bicifadine formulation
CN1492757A (en) Use of accelerated lymphocyte homing agents for manufacture of medicament for treating delayed graft function in tissue transplant
CN1053441C (en) Compound with 1-(aryl Chain olefine)-4-(aryl methyl) piperazine structure, preparation process thereof and medicine thereof
CN1418630A (en) Solution agent of antiallergi medicine contg. levocetirizine
CN1468601A (en) Picroside-II as one new medicine for preventing and treating allergic and inflammatory diseases
CN1108095A (en) Composition for prophylaxis and treatment of myopia
CN1759887A (en) Mucous membrane absorption ingestion type medicinal composition for drawing out interferon, and preparation
CN1708308A (en) Use of fosinopril to reduce cardiovascular events in dialysis patients
AU2002346859A1 (en) Macrolides containing pharmaceutical compositions
CN1327386A (en) Anti-HIV infection agents and method for treating HIV infection
CN1524518A (en) Use of 2-amino-2(2-(4-octyl phenyl)ethyl)-1,3-propylene glycol in the preparation of medicaments of preventing and curing immune liver injury
CN1579389A (en) Compound preparation for treating hypertension
CN87107599A (en) 4-hydroxyl-4-(substituted alkenyl base) hexahydrobenzoic acid

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20070404

Termination date: 20131022